Abstract
Behçet’s disease (BD) is a chronic relapsing vasculitis with multifunctional pathogenesis. The mucocutaneous and ocular lesions are the commonest manifestations, but BD also affects the musculoskeletal, intestinal, cardiac, and central nervous system. BD therapy is based on the suppression of the inflammatory process, using immunomodulating and immunosuppressive agents. In selected cases, invasive procedures may be required.
Similar content being viewed by others
Abbreviations
- BD:
-
Behcet disease
- IL:
-
Interleukin
- TNFα:
-
Tumor Necrosis Factor
- PTX:
-
Pentoxifylline
- CsA:
-
Cyclosporin A
- AZA:
-
Azathioprine
- IFNα:
-
Interferon α
- ANA:
-
Antinuclear antibodies
- MMP:
-
Matrix metalloprotease
- CNS:
-
Central nervous system
- CSF:
-
Cerebrospinal fluid
References
Alpsoy E, Akman A (2009) Behçet’s disease: an algorithmic approach to its treatment. Arch Dermatol Res 301:693–702
Ahmad T, Wallace GR, James T et al (2003) Mapping the HLA association in Behçet’s disease: a role for tumor necrosis factor polymorphisms? Arth Rheum 48:807–813
Ceyran H, Akcali Y, Kahraman C (2003) Surgical treatment of vasculo-Behçet’s disease. A review of patients with concomitant multiple aneurysms and venous lesions. Vasa 32:149–153
Kapsimali V, Kanakis M, Vaiopoulos G, et al (2010) Etiopathogenesis of Behçet’s disease with emphasis on the role of immunological aberrations. Clin Rheumatol (in press)
Calamia KT, Kaklamanis PG (2008) Behçet’s disease: recent advances in early diagnosis and effective treatment. Curr Rheumatol Rep 10:349–355
Gul A (2007) Standard and novel therapeutic approaches to Behçet’s disease. Drugs 67:2013–2022
Sfikakis PP, Theodossiadis PG, Katsiari CG et al (2001) Effect of infliximab on sight-threatening panuveitis in Behçet’s disease. Lancet 358:295–296
Lynde CB, Bruce AS, Rogers RS 3rd (2009) Successful treatment of complex aphthosis with colchicine and dapsone. Arch Dermatol 145:273–276
Debol SM, Herron MJ, Nelson RD (1997) Anti-inflammatory action of dapsone: inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transduction. J Leukoc Biol 62:827–836
Kaklamanis P, Kaklamani V (2001) Treatment of Behçet’s disease—an update. Semin Arth Rheum 30:299–312
Hatemi G, Silman A, Bang D et al (2009) Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease. Ann Rheum Dis 68:1528
Seyahi E, Fresko I, Yazici H et al (2006) The management of Behcet syndrome. Acta Rheum Port 31:125–131
Lin P, Liang G (2006) Behçet disease: recommendation for clinical management of mucocutaneous lesions. J Clin Rheumatol 12:282–286
Duygulu F, Evereklioglu MM et al (2005) Synovial nitric oxide concentrations are increased and correlated with serum levels in patients with active Behçet’s disease: a pilot study. Clin Rheumatol 24:324–330
Sfikakis PP, Markomichelakis N, Alpsoy E et al (2007) Anti-TNF therapy in the management of Behcet’s disease—review and basis for recommendations. Rheumatology (Oxford) 46:736–741
Dé Tran QH, Guay E, Chartier S, Tousignant J (2001) Tacrolimus in dermatology. J Cutan Med Surg 5:329–335
Bruynzeel I, Van Der Raaij LM, Willemze R, Stoof TJ (1997) Pentoxifylline inhibits human T-cell adhesion to dermal endothelial cells. Arch Dermatol Res 289:189–193
Funk JO, Ernst M, Schonharting MM, Zabel P (1995) Pentoxifylline exerts synergistic immunomodulatory effects in combination with dexamethasone or cyclosporin A. Int J Immunopharmacol 17:1007–1016
Zouboulis CC, Orfanos CE (1998) Treatment of Adamantiades-Behçet disease with systemic interferon alfa. Arch Dermatol 134:1010–1016
Nakamura T, Yagi H, Kurachi K, Konno H (2006) Intestinal Behcet’s disease with pyoderma gangrenosum: a case report. World J Gastroenterol 12:979–981
Fresko I, Yazici H (2008) Treatment strategies for Behçet’s disease. Expert Opin Pharmacother 9:3211–3219
Choi IJ, Kim JS, Cha SD et al (2000) Long-term clinical course and prognostic factors in intestinal Behçet’s disease. Dis Colon Rectum 43:692–700
Lee KS, Kim SJ, Lee BC et al (1997) Surgical treatment of intestinal Behçet’s disease. Yonsei Med J 38:455–460
Kurata M, Nozue M, Seino K et al (2006) Indications for surgery in intestinal Behçet’s disease. Hepatogastroenterology 53:60–63
Sapadin AN, Fleischmajer R (2006) Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 54:258–265
Deuter CM, Kotter I, Wallace GR et al (2008) Behçet’s disease: ocular effects and treatment. Prog Retin Eye Res 27:111–136
Kaçmaz RO, Kempen JH, Newcomb C et al (2008) Systemic immunosuppressive therapy for eye diseases cohort study group. Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuity. Am J Ophthalmol 146:828–836
Tugal-Tutkun I, Mudun A, Urgancioglu M et al (2005) Efficacy of Infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine and corticosteroids in Behcet disease: an open-label trial. Arthritis Rheum 52:2478–2484
Yazici H, Pazarli H, Barnes CG et al (1990) A controlled trial of azathioprine in Behçet’s syndrome. N Engl J Med 322:281–285
Akman-Demir G, Ayranci O, Kurtuncu M et al (2008) Cyclosporine for Behçet’s uveitis: is it associated with an increased risk of neurological involvement? Clin Exp Rheumatol 26(Suppl):S84–S90
Krause L, Altenburg A, Pleyer U et al (2008) Longterm visual prognosis of patients with ocular Adamantiades-Behçet’s disease treated with interferon-alpha-2a. J Rheumatol 35:896–903
Tugal-Tutkun I, Onal S, Altan-Yaycioglu R et al (2006) Neovascularization of the optic disc in Behçet’s disease. Jpn J Ophthalmol 50:256–265
Sfikakis PP (2002) Behçet’s disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 61(Suppl 2):ii51–ii53
Elezoglou A, Kafasi N, Kaklamanis PH et al (2007) Infliximab treatment-induced formation of autoantibodies is common in Behçet’s disease. Clin Exp Rheumatol 25(Suppl):S65–S69
Krause L, Altenburg A, Bechrakis NE et al (2007) Intraocular surgery under systemic interferon-alpha therapy in ocular Adamantiades-Behçet’s disease. Graefes Arch Clin Exp Ophthalmol 245:1617–1621
Elgin U, Berker N, Batman A, Soykan E (2007) Nd:YAG laser iridotomy in the management of secondary glaucoma associated with Behçet’s disease. Eur J Ophthalmol 17:191–195
Sullu Y, Alotaiby H, Beden U, Erkan D (2005) Pars plana vitrectomy for ocular complications of Behçet’s disease. Ophthalmic Surg Lasers Imaging 36:292–297
Soylu M, Demircan N, Pelit A (2001) Pars plana vitrectomy in ocular Behçet’s disease. Int Ophthalmol 24:219–223
Han JK, Kim HK, Kim YJ et al (2009) Behçet’s disease as a frequently unrecognized cause of aortic regurgitation: suggestive and misleading echocardiography findings. J Am Soc Echocardiogr 22:1269–1274
Marzban M, Mandegar MH, Karimi A et al (2008) Cardiac and great vessel involvement in “Behcet’s disease”. J Card Surg 23:765–768
Imazio M, Brucato A, Trinchero R et al (2009) Colchicine for pericarditis: hype or hope? Eur Heart J 30:532–539
Arishiro K, Nariyama J, Hoshiga M et al (2006) Vascular Behçet’s disease with coronary artery aneurysm. Intern Med 45:903–907
Ozen S, Bilginer Y, Besbas N et al (2010) Behçet disease: treatment of vascular involvement in children. Eur J Pediatr 169:427–430
Oh SH, Lee JH, Shin JU, Bang D (2008) Dermatological features in Behçet disease-associated vena cava obstruction. Br J Dermatol 159:555–560
Alpagut U, Ugurlucan M, Dayioglu E (2007) Major arterial involvement and review of Behçet’s disease. Ann Vasc Surg 21:232–239
Abdul-Hussien H, Hanemaaijer R, Verheijen JH et al (2009) Doxycycline therapy for abdominal aneurysm: improved proteolytic balance through reduced neutrophil content. J Vasc Surg 49:741–749
Siva A, Saip S (2009) The spectrum of nervous system involvement in Behçet’s syndrome and its differential diagnosis. J Neurol 256:513–529
Borhani Haghighi A (2009) Treatment of neuro-Behçet’s disease: an update. Expert Rev Neurother 9:565–574
Gono T, Murata M, Kawaguchi Y et al (2009) Successful treatment for sympathetic storms in a patient with neuro-Behçet’s disease. Clin Rheumatol 28:357–359
Disclosures
None
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Alexoudi, I., Kapsimali, V., Vaiopoulos, A. et al. Evaluation of current therapeutic strategies in Behçet’s disease. Clin Rheumatol 30, 157–163 (2011). https://doi.org/10.1007/s10067-010-1566-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-010-1566-4